Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells

被引:0
|
作者
Lanza, F
Castoldi, GL
Castagnari, B
Todd, RF
Moretti, S
Spisani, S
Latorraca, A
Focarile, E
Roberti, MG
Traniello, S
机构
[1] Univ Ferrara, Dept Biomed Sci & Adv Therapies, Sect Haematol, I-44100 Ferrara, Italy
[2] Univ Ferrara, Dept Biochem & Mol Biol, I-44100 Ferrara, Italy
[3] Univ Michigan, Dept Hematol Oncol, Ann Arbor, MI 48109 USA
关键词
UPA-R; acute myeloid leukaemia; AML M5 morphology; tissue infiltration; chromosome abnormalities;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Urokinase-type plasminogen activator receptor (UPA-R-CD87) is a GPI-anchored membrane protein which promotes the generation of plasmin on the surface of many cell types, probably facilitating cellular extravasation and tissue invasion. A now cytometric quantitative analysis of expression levels for UPA-R was performed on fresh blast cells from patients with acute myeloid leukaemia (AML, n = 74), acute lymphoblastic leukaemia (ALL, n = 24), and biphenotypic leukaemia (BAL, n = 3) using two CD87 monoclonal antibodies (McAbs) (3B10 and VIM5). Peripheral blood and bone marrow (BM) cells from 15 healthy adults served as controls, Using 3B10 McAb, UPA-R was expressed (>99%) by blood monocytes, neutrophils, and BM myelomonocytic precursors in controls, whereas resting T and B lymphocytes, and CD34(+) cells were UPA-R negative, We also attempted to clarify whether UPA-R has a role in mediating neutrophil functions. Oriented locomotion induced by different chemotaxins and lysozyme release by granules stimulated with fMLP or PMA were significantly decreased when UPA-R was neutralized by CD87 McAb. In contrast, the anti-UPA-R McAb had no effect on superoxide anion generation of normal neutrophils. Blasts from AML showed a heterogenous pattern of expression for the UPA-R McAbs, with reactivity strictly dependent on FAB subtype. The highest UPA-R expression was seen in the M5 group: all patients tested (n = 20) showed strong positivity for the WA-R McAb whereas only 12% (3/24) of ALL patients were CD87 positive, and 2/3 of BAL patients showed a dim expression for CD87. The number of receptors expressed by blast cells in 6/74 (8.1%) AML patients was higher than those of normal samples; in addition, since co-expression of UPA-R and CD34 was not found in normal haemopoietic cells, it may be postulated that CD87 can be used alone (when over-expressed) or in combination with CD34 for the detection of minimal residual disease. Results also indicated that patients with UPA-receptors > 12 x 10(3) ABC/cell, irrespective of FAB subtype, had a greater tendency for cutaneous and tissue infiltration and a higher frequency of chromosome abnormalities, thus suggesting the concept that cellular UPA-R content positively correlates with the invasive potential of AML cells. The combination of higher UPA-R positivity, abnormalities of chromosome 11, and M5 FAB morphology may identify a peculiar subset of AML, characterized by a more aggressive clinical course.
引用
收藏
页码:110 / 123
页数:14
相关论文
共 50 条
  • [31] Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells
    Sprague, Lisa D.
    Tomaso, Herbert
    Mengele, Karin
    Schilling, Daniela
    Bayer, Christine
    Stadler, Peter
    Schmitt, Manfred
    Molls, Michael
    ONCOLOGY REPORTS, 2007, 17 (05) : 1259 - 1268
  • [32] EXPRESSION OF THE RECEPTOR FOR UROKINASE-TYPE PLASMINOGEN-ACTIVATOR IN NORMAL AND NEOPLASTIC BLOOD-CELLS AND HEMATOPOIETIC-TISSUE
    PLESNER, T
    RALFKIAER, E
    WITTRUP, M
    JOHNSEN, H
    PYKE, C
    PEDERSEN, TL
    HANSEN, NE
    DANO, K
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1994, 102 (06) : 835 - 841
  • [33] Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas
    Foca, C
    Moses, EK
    Quinn, MA
    Rice, GE
    GYNECOLOGIC ONCOLOGY, 2000, 79 (02) : 244 - 250
  • [34] The diagnostic value of serum urokinase-type plasminogen activator receptor in acute appendicitis
    Aygun, Ali
    Gunaydin, Mucahit
    Ozozan, Omer Vefik
    Cihan, Murat
    Karakahya, Murat
    ULUSAL TRAVMA VE ACIL CERRAHI DERGISI-TURKISH JOURNAL OF TRAUMA & EMERGENCY SURGERY, 2019, 25 (05): : 467 - 473
  • [35] Role of urokinase-type plasminogen activator in local immunotherapy
    Takeda, T
    Ito, Y
    Wakasugi, E
    Kobayashi, T
    Monden, M
    ONCOLOGY REPORTS, 1998, 5 (02) : 329 - 333
  • [36] Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors
    Yoshizawa, Kunio
    Nozaki, Shinichi
    Kitahara, Hiroko
    Kato, Koroku
    Noguchi, Natsuyo
    Kawashiri, Shuichi
    Yamamoto, Etsuhide
    ONCOLOGY REPORTS, 2011, 26 (06) : 1555 - 1560
  • [37] Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells
    Hjertner, Ö
    Qvigstad, G
    Hjorth-Hansen, H
    Seidel, C
    Woodliff, J
    Epstein, J
    Waage, A
    Sundan, A
    Börset, M
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (04) : 815 - 822
  • [38] Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer
    de Bock, CE
    Wang, Y
    MEDICINAL RESEARCH REVIEWS, 2004, 24 (01) : 13 - 39
  • [39] Expression of urokinase-type plasminogen activator receptor (uPAR) in primary CNS neoplasms
    Rudnicki, A
    Hutzler, M
    Smith, TW
    LABORATORY INVESTIGATION, 2001, 81 (01) : 209A - 209A
  • [40] Expression of urokinase-type plasminogen activator receptor (uPAR) in primary CNS neoplasms
    Rudnicki, A
    Hutzler, M
    Smith, TW
    MODERN PATHOLOGY, 2001, 14 (01) : 209A - 209A